The earnings call highlighted strong revenue growth and profitability improvements, particularly in the MedTech and Mechanical Thrombectomy segments. The company increased its guidance for fiscal 2025, indicating confidence in future performance. However, there are ongoing challenges with NanoKnife reimbursement and minimal growth in the Med Device segment. Overall, the positive aspects significantly outweigh the lowlights.

Company Guidance -

Q4 2025

During the AngioDynamics Fiscal Year 2025 Third Quarter Earnings Call, the company increased its guidance for the year following strong performance. Total worldwide revenue was reported at $72 million, marking a 9% year-over-year increase. The MedTech segment grew by 22%, driven by platforms like Auryon, which saw a 17% increase, and the Mechanical Thrombectomy business, which grew by approximately 47%. The company's gross margin improved to 54%, up by 290 basis points compared to the previous year. Adjusted EBITDA turned positive at $1.3 million, contrasting with a $3.6 million loss in the same quarter of the previous fiscal year, and adjusted EPS was a loss of $0.08 per share, an improvement from the $0.16 loss per share recorded last year. AngioDynamics' updated guidance projects fiscal 2025 total revenue between $285 million and $288 million, with MedTech growth expected to be 14% to 16% and a gross margin range of 53% to 54%.

Strong Revenue Growth

Total worldwide revenue was $72 million, representing growth of over 9% year-over-year. MedTech segment grew 22%, and Auryon platform revenue increased by 17%.

Mechanical Thrombectomy Segment Success

Mechanical Thrombectomy products, AlphaVac and AngioVac, in combination grew approximately 47% over the second quarter of last year. AlphaVac revenue increased by over 160%.

Improving Profitability

Reported positive adjusted EBITDA of $1.3 million compared to a loss of $3.6 million in the prior year. Adjusted EPS loss improved from $0.16 to $0.08 per share.

Guidance Increase

Guidance increased for total revenue, MedTech growth, gross margin, adjusted EBITDA, and adjusted EPS for the fiscal year 2025.

AngioDynamics (ANGO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ANGO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 09, 2025	2025 (Q4)	-0.12 / -	-0.06	―	―	―
Apr 02, 2025	2025 (Q3)	-0.13 / -0.08	-0.16	50.00% (+0.08)
Jan 08, 2025	2025 (Q2)	-0.11 / -0.04	-0.05	20.00% (+0.01)
Oct 03, 2024	2025 (Q1)	-0.15 / -0.11	-0.12	8.33% (<+0.01)
Jul 16, 2024	2024 (Q4)	-0.17 / -0.06	0.02	-400.00% (-0.08)
Apr 04, 2024	2024 (Q3)	-0.15 / -0.16	-0.03	-433.33% (-0.13)
Jan 05, 2024	2024 (Q2)	-0.07 / -0.05	0.01	-600.00% (-0.06)
Oct 04, 2023	2024 (Q1)	-0.13 / -0.12	-0.06	-100.00% (-0.06)
Jul 12, 2023	2023 (Q4)	0.02 / 0.02	0.01	100.00% (+0.01)
Mar 30, 2023	2023 (Q3)	>-0.01 / -0.03	0.03	-200.00% (-0.06)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ANGO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 02, 2025	$9.66	$10.86	+12.42%
Jan 08, 2025	$9.40	$12.94	+37.66%
Oct 03, 2024	$7.65	$6.37	-16.73%
Jul 16, 2024	$5.93	$7.51	+26.64%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.